Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP publication examining how emerging life science programs can translate into
· Jiangsu: 81 Projects Win China Patent Awards · Beijing: 104 Invention Patents Win 26th China Patent Award · Second Session of the 26th China Patent
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Insight, a MeritsIP publication examining how emerging life science programs can translate into
The successful launch of CAR-T drugs has made cell therapy a hotspot in biopharmaceutical research and development, sparking a global wave of patent deployment. Faced with
CCR8-targeted Treg clearing + ITGB6-targeted ADC,—— two differentiatedpipelines in a single biotech core judgment: This asset portfolio includes two independent and complementary pipelines: one CCR8-targeted ADCC
License-in and License-out are the two core models in biopharmaceutical BD transactions—the former buys equity with money, while the latter sells equity for money. Behind this lies
AI is deeply penetrating the pharmaceutical industry from drug target discovery to clinical trials, but the unconventional R&D model of AI pharmaceuticals also brings entirely new
August 20-22,First-in-the-line drug early R&D and translation conferenceIn Beijing, it was also the Zhuang dynastyLin SongyuanThe hotel was successfully held. The conference brings together regulatory agencies,Multinational
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Insight, a MeritsIP publication examining how emerging life science programs can translate into
Intellectual property isBD tradingThe core target in the market. In transactions worth hundreds of millions or even billions of dollars, IP serves as the pricing anchor—buyers